Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stem cell secretions for perianal fistula in Crohn's disease
IRCT20200809048342N2Phase 2Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Sep 2021
- Modality
- Stem Cell Therapies → Cell Therapies, Cell Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of wharton's jelly mesenchymal stromal cells, mesenchymal stem cell secretome and nepidermin in Crohn's disease (3 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: MRI assessment of fistula response, Blood test follow-up and 3 more. Started Sep 2021; status: completed.
02
Drugs
wharton's jelly mesenchymal stromal cellsmesenchymal stem cell secretomenepidermin
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on IRCT20200809048342N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200809048342N2.